Many receptors, by design.
"Poliagonist" names no number. It takes poli-, the Romanian form of poly-, and says only many: one engineered amino acid chain that speaks to more than one receptor, without deciding in advance how many. That is deliberately the general case — the numbered rungs each have their own page, and this one holds the question they all descend from: why engage several receptors with a single chain at all, and what does the word "agonist" have to carry for that to mean anything?
The Poliagonist programme
At Panacea Bio Chem, Bogdan Dicoias runs an amino acid chain (AAC) design practice: sequences are engineered residue by residue, folded, and profiled against receptor panels. The Poliagonist series is the count-free end of that practice: the programme fixes the method — one chain, tuned position by position, addressing a chosen receptor set — and leaves the size of that set as an outcome of the design rather than a headline decided before the work. Where a specific count is the subject, it belongs on the page that owns that count, not here.
Honesty boundary: this is a design-stage research programme. We publish the concept, the public science it stands on, and the design philosophy — we do not claim a finished molecule, binding data, or any clinical result here. The specific receptor constellation and sequence work remain Panacea intellectual property while the programme matures.
Illustrative programme disclosure · no results are claimed on this page
"The field counted one, then two, then three — and each step looked excessive until it worked. We do not assume the counting stops at three. An amino acid chain has enough addressable surface to speak to more than one receptor; the craft is choosing which voices belong in one chord, and tuning every residue so the chord holds."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
Agonism, from the ground up
Receptors are the cell's antennas — proteins that read chemical signals and convert them into action. The vocabulary of modern pharmacology begins with two words.
Agonist — the switch-on
An agonist binds a receptor and activates it, standing in for the body's own signal. Insulin, adrenaline and GLP-1 all act through receptors; the medicines built on them are agonists.
Antagonist — the blockade
An antagonist occupies the same docking site but flips nothing: it physically prevents the natural signal from getting through. Beta-blockers and antihistamines are everyday examples.
Selectivity — the classic bargain
For a century the art of drug design was narrowing: one molecule, one receptor, minimal cross-talk. Fewer targets meant fewer surprises — and, often, less reach than a disease demands.
Polyagonism — the deliberate opposite
Metabolic and neurological diseases are network problems. Morphy and Rankovic formalised the counter-strategy in 2005: design one ligand to engage several receptors on purpose — a "designed multiple ligand" (J. Med. Chem. 2005).
Where the word came from: 120 years of receptors
Before anyone could design a molecule for several receptors, the receptor itself had to be argued into existence — and then split into kinds. Four moments carry that argument, and they are why a page that claims no number can still say something exact.
1905 — a "receptive substance"
Working on nicotine and curare in striated muscle, John Newport Langley argued that the drug acts on a receptive substance belonging to the cell, not on the nerve ending and not on the contractile machinery. It is the first clean statement of the thing every agonist is an agonist of (Langley, J. Physiol. 1905).
1948 — one receptor becomes two
Raymond Ahlquist ranked six sympathomimetic amines by potency, tissue by tissue, and found the order itself changed with the tissue — which a single receptor cannot do. He concluded there were two adrenotropic receptors, alpha and beta (Ahlquist, Am. J. Physiol. 1948). Receptor subtypes begin here, and with them the idea that "which receptors" is a choice a designer makes.
2012 — the targets become visible
Robert Lefkowitz and Brian Kobilka shared the Nobel Prize in Chemistry for the studies of G-protein-coupled receptors that turned Ahlquist's inference into isolated, sequenced and finally crystallised proteins (Nobel Prize in Chemistry 2012). A designer can aim at a structure; nobody can aim at an inference.
2005 — aiming at several on purpose
Richard Morphy and Zoran Rankovic gave the counter-strategy its name: the designed multiple ligand, one molecule built to engage several targets deliberately rather than by accident of promiscuity (Morphy & Rankovic, J. Med. Chem. 2005). The rest of this page is a consequence of that sentence.
Two words still do the work. An agonist binds a receptor and switches it on, standing in for the body's own signal; an antagonist occupies the same site and lets nothing through. For a century the craft was narrowing — one molecule, one receptor, as little cross-talk as could be managed. A designed multiple ligand is the deliberate opposite, and it is only coherent because 1905 and 1948 happened first.
Why "poli-" does not name a number
The rest of the Panacea agonist lane counts. This page does not, and the difference is the point: a count is a commitment, and a commitment made before the design work is a claim nobody has earned yet.
What the name actually says
Poli- is the Romanian spelling of the Greek poly-, "many". It is a quantity word with no quantity in it — which is exactly the commitment this programme is willing to make in public: more than one receptor, addressed on purpose, by one chain. How many is a result, not a promise.
What the public record has reached
Two receptors: tirzepatide, a GIP/GLP-1 peptide, outperformed semaglutide on glucose control in type 2 diabetes (Frías et al., N. Engl. J. Med. 2021) and reached roughly 20.9% mean body-weight reduction over 72 weeks (Jastreboff et al., N. Engl. J. Med. 2022). Three: retatrutide added the glucagon receptor, about 24.2% at 48 weeks in phase 2 (Jastreboff et al., N. Engl. J. Med. 2023). The two tirzepatide readouts are SURPASS-2 and SURMOUNT-1, and the drug is approved by the FDA as Mounjaro (2022) and Zepbound (2023). Retatrutide has since reached phase 3: TRIUMPH-4 (Lilly, December 2025) reported about 28.7% mean weight loss at 68 weeks, the first successful phase 3 for a triple agonist (Lilly announcement).
Two is not one story
The incretin pair is not the only dual in the clinic, and reading only the Western trial record makes it look as though it were. Mazdutide, a GLP-1/glucagon dual peptide developed by Innovent Biologics with Eli Lilly, was tested once-weekly in Chinese adults with obesity or overweight (Ji et al., N. Engl. J. Med. 2025), and its 9-mg dose was reported in the GLORY-2 randomised clinical trial (Gao et al., JAMA 2026). Different receptor pair, different trial population, same design idea.
Why one chain rather than two drugs
Matthias Tschöp and Richard DiMarchi call it unimolecular polypharmacy: one molecule carries a fixed ratio of activities, so the balance between receptors is engineered once and travels with the dose instead of being re-created by two separate pharmacokinetic curves (Tschöp et al., Cell Metab. 2016; the first unimolecular dual incretins, Finan et al., Sci. Transl. Med. 2013).
Which page answers which question
This lane is split deliberately so that no two pages argue the same point. If you arrived looking for a number, it is answered elsewhere:
- octogonist.com — the eight-receptor case, specifically.
- multiagonist.com — the numbered ladder rung by rung, and which rungs have public evidence behind them.
- decagonist.com — the ten-receptor frontier and what would have to be true to reach it.
- multigonist.com — polypharmacology as a design theory, and why peptides are the scaffold it is attempted on.
Disclosure: a concept, not a compound
Nothing on this page is a result of ours. The medicines named above belong to the companies that ran the trials, and every trial is cited so a reader can check it without going through us.
On the page
Where the receptor idea came from, what "designed multiple ligand" means, the published trial record of the duals and the triple, and the reason Panacea's count-free programme is stated as a direction rather than a number.
Not on the page
Receptor sets, sequences, folding routes, assay output, timelines. None of it is withheld as a tease — a programme of this kind earns its claims in the literature, and until it has, a webpage is the wrong place for them.
Frequently asked questions
What does the name Poliagonist mean?
"Poli-" is the Romanian form of the Greek poly-, meaning many. The name says that one engineered peptide engages more than one receptor on purpose — and deliberately says nothing about how many.
Does the Poliagonist programme commit to a specific number of receptors?
No, and that is the distinction from the numbered pages in this lane. The programme commits to the method — one chain, one engineered balance of activities — and treats the size of the receptor set as an outcome of the design work rather than a figure announced ahead of it.
How many receptors has a marketed peptide actually engaged?
Two and three are what the published record carries: tirzepatide at GIP and GLP-1, mazdutide at GLP-1 and glucagon, and retatrutide at GIP, GLP-1 and glucagon in phase 2. Each is cited above with its trial. Nothing beyond three has a comparable public record, and this page does not supply one.
How is this page different from Panacea's other agonist pages?
It holds the general case and the history. The counts live on octogonist.com (eight), decagonist.com (ten) and multiagonist.com (the ladder, rung by rung); the design theory lives on multigonist.com. The credited timeline behind all of them is on The Research, and further questions on the Questions page.
What is a receptor agonist?
A molecule that binds a receptor and switches it on, mimicking the body's own signal. An antagonist binds the same site and blocks the signal instead.
What is a multi-receptor agonist?
One molecule engineered to activate several receptors at once — a designed multiple ligand. Tirzepatide (two) and retatrutide (three) are the clinical landmarks.
Does an eight-receptor agonist exist as a medicine?
No approved medicine engages many receptors by design; the clinical frontier today is triple agonism. Panacea's Poliagonist series is a design-stage programme, presented as such.
Who pioneered multi-agonist peptides?
Morphy and Rankovic formalised designed multiple ligands in 2005; Tschöp and DiMarchi advanced unimolecular polypharmacology; Eli Lilly brought tirzepatide and retatrutide to the clinic. The credited timeline is on The Research.
Trending in the field
Recent developments in the field — refreshed 2026-07-26 by Panacea Bio Chem.
